ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVOT, cardiovascular outcomes trial; DPP-4, dipeptidyl peptidase 4; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; GLP-1 RAs, glucagon-like peptide 1 receptor agonists; HF, heart failure; NASH, nonalcoholic steatohepatitis; SGLT2, sodium–glucose cotransporter 2; SQ, subcutaneous; T2D, type 2 diabetes.

*For agent-specific dosing recommendations, please refer to the manufacturers’ prescribing information.

†FDA-approved for cardiovascular disease benefit.

‡FDA-approved for heart failure indication.

§FDA-approved for chronic kidney disease indication.